drugset
drugset / Trial / NCT05398614

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

NCT05398614 ↗

Phase 1 Unknown 18 enrolled Hebei Senlang Biotechnology Inc., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.

Timeline

Start
2022-05-01
Primary completion
2023-12-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SENL101 Cell therapy — —

Indications

T-cell acute lymphoblastic leukemia T-cell non-Hodgkin lymphoma